COVID-19: New EMCDDA study highlights decline in stimulant drug use but some rises in the use of cannabis, alcohol and prescription medicines to combat anxiety and depression

A decline in stimulant drug use but some rises in the consumption of cannabis and licit substances are among the findings presented today in a new EMCDDA report The impact of COVID-19 on patterns of drug use and drug-related harms in Europe. The report describes how national confinement measures and disrupted street drug markets have reduced both the opportunities to use drugs within social environments as well as the availability of some substances.

23.06.2020 

Other news